Third, we demonstrated the pharmacological degradation of WDR5 by PROTAC to be superior to the match WDR5 PPI inhibitor for the SS treatment, and the tumor-killing effects by MS67 are much more potent in the SS18::SSX-positive SS cells, when compared to non-SS sarcoma cells that do not carry SS18::SSX. Here, WDR5 is linked to sarcoma.